Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096628 | 0.88 | PGR (0.58) | CCR2PGRERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL7597807 | 0.87 | CCR2 (0.71) | CCR2PGRAPPERBB2HSP90AA1 | |
| SCHEMBL28591171 | 0.85 | APP (0.61) | CCR2APPLMNAALDH1A1 | |
| SCHEMBL2766570 | 0.82 | ERBB2 (0.68) | CCR2PGRERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL2968297 | 0.82 | HSD17B2 (0.67) | CCR2HSD17B2 | |
| SCHEMBL1441860 | 0.81 | KDM1A (0.48) | CCR2LMNAALDH1A1 | |
| SCHEMBL1443646 | 0.80 | FFAR4 (0.52) | CCR2APPERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL14057177 | 0.80 | CCR2 (0.49) | CCR2PGRLMNAALDH1A1 | |
| SCHEMBL9933533 | 0.79 | CCR2 (0.81) | CCR2PGRHSD17B2 | |
| SCHEMBL12096927 | 0.78 | FFAR4 (0.49) | CCR2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| EP-2475642-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | Laboratoires Fournier S.A. (FR) | 2012-07-18 | — | — | EP | disclosed |
| CN-102596906-A | Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease | FOURNIER LAB SA | 2012-07-18 | — | — | CN | disclosed |
| WO-2011030068-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | LABORATOIRES FOURNIER SA (FR) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | CCR2 729/4885PGR 712/4885APP 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.